A Phase 1, Randomized, Open-Label, Two-Way Crossover Study of Two Oral Formulations of LX1033 in Healthy Human Subjects.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs LX 1033 (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics
- 19 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.